Pfizer 2007 Annual Report Download - page 19

Download and view the complete annual report

Please find page 19 of the 2007 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 85

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85

2007 Financial Report 17
Financial Review
Pfizer Inc and Subsidiary Companies
Revenues—Major Pharmaceutical Products
Revenue information for several of our major Pharmaceutical products follow:
(MILLIONS OF DOLLARS) YEAR ENDED DEC. 31, % CHANGE
_____________________________________ ________________
PRODUCT PRIMARY INDICATIONS 2007 2006 2005 07/06 06/05
Cardiovascular and
metabolic diseases:
Lipitor Reduction of LDL cholesterol $12,675 $12,886 $12,187 (2) 6
Norvasc Hypertension 3,001 4,866 4,706 (38) 3
Chantix/Champix An aid to smoking cessation 883 101 — 773 *
Caduet Reduction of LDL cholesterol and hypertension 568 370 185 54 99
Cardura Hypertension/Benign prostatic hyperplasia 506 538 586 (6) (8)
Central nervous system
disorders:
Lyrica Epilepsy, post-herpetic neuralgia and diabetic
peripheral neuropathy, fibromyalgia 1,829 1,156 291 58 297
Geodon/Zeldox Schizophrenia and acute manic or mixed episodes
associated with bipolar disorder 854 758 589 13 29
Zoloft Depression and certain anxiety disorders 531 2,110 3,256 (75) (35)
Neurontin Epilepsy and post-herpetic neuralgia 431 496 639 (13) (22)
Aricept(a) Alzheimer’s disease 401 358 346 12 4
Xanax/Xanax XR Anxiety/Panic disorders 325 316 409 3(23)
Relpax Migraine headaches 315 286 233 10 23
Arthritis and pain:
Celebrex Arthritis pain and inflammation, acute pain 2,290 2,039 1,730 12 18
Infectious and respiratory
diseases:
Zyvox Bacterial infections 944 782 618 21 27
Vfend Fungal infections 632 515 397 23 30
Zithromax/Zmax Bacterial infections 438 638 2,025 (31) (69)
Diflucan Fungal infections 415 435 498 (5) (13)
Urology:
Viagra Erectile dysfunction 1,764 1,657 1,645 61
Detrol/Detrol LA Overactive bladder 1,190 1,100 988 811
Oncology:
Camptosar Metastatic colorectal cancer 969 903 910 7—
Sutent Advanced and/or metastatic renal cell carcinoma (mRCC)
and refractory gastrointestinal stromal tumors (GIST) 581 219 — 166 *
Aromasin Breast cancer 401 320 247 25 30
Ophthalmology:
Xalatan/Xalacom Glaucoma and ocular hypertension 1,604 1,453 1,372 10 6
Endocrine disorders:
Genotropin Replacement of human growth hormone 843 795 808 6(2)
All other:
Zyrtec/Zyrtec D Allergies 1,541 1,569 1,362 (2) 15
Alliance revenue Alzheimer’s disease (Aricept), neovascular (wet)
age-related macular degeneration (Macugen),
Parkinson’s disease (Mirapex), hypertension
(Exforge and Olmetec), multiple sclerosis (Rebif)
and chronic obstructive pulmonary disease (Spiriva) 1,789 1,374 1,065 30 29
(a) Represents direct sales under license agreement with Eisai Co., Ltd.
* Calculation not meaningful.
Certain amounts and percentages may reflect rounding adjustments.